**Supplementary Table 1. Multivariate models of clinical outcomes and histological progression**

 Clinical outcomes (n=433, AIC = 710)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Estimate** | **Standard Error** | **p-value** | **Hazard ratio** **(95% CI)** |
| Bilirubin | 0.883 | 0.273 | 0.001 | 2.42 (1.42, 4.13) |
| INR > 1.0 | 0.809 | 0.280 | 0.004 | 2.25 (1.30, 3.89) |
| Albumin | -1.63 | 0.343 | <0.001 | 0.20 (0.10, 0.38) |
| Log YKL-40 | 0.89 | 0.327 | 0.007 | 2.44 (1.28, 4.63) |

Histological progression (n=209, AIC =335)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Estimate** | **Standard error** | **p-value** | **Hazard ratio****(95% CI)** |
| Platelets \* | -0.328 | 0.118 | 0.005 | 0.72 (0.57, 0.91) |
| Log HA | 0.883 | 0.313 | 0.005 | 2.42 (0.27, 4.47) |
| 24 month biopsy ^ | -2.237 | 0.824 | 0.007 | 0.11 (0.02, 0.54) |
| 48 month biopsy ^ | -1.821 | 0.819 | 0.026 | 0.16 (0.03, 0.81) |

\* per 50,000 platelets/ ml ^ The coefficients for 24 and 48 month biopsy are used to estimate the baseline survival function of histological progression in this complementary log-log model